Equities research analysts expect Cytosorbents Corp (NASDAQ:CTSO) to post ($0.10) earnings per share for the current quarter, according to Zacks. Two analysts have made estimates for Cytosorbents’ earnings, with the highest EPS estimate coming in at ($0.07) and the lowest estimate coming in at ($0.14). Cytosorbents posted earnings of ($0.16) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 37.5%. The business is scheduled to report its next earnings report on Friday, March 2nd.
On average, analysts expect that Cytosorbents will report full-year earnings of ($0.26) per share for the current fiscal year, with EPS estimates ranging from ($0.31) to ($0.23). For the next year, analysts expect that the company will post earnings of ($0.39) per share, with EPS estimates ranging from ($0.45) to ($0.35). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Cytosorbents.
Several brokerages have recently commented on CTSO. B. Riley restated a “buy” rating and issued a $11.25 target price on shares of Cytosorbents in a research note on Thursday, January 25th. HC Wainwright restated a “buy” rating and issued a $14.00 target price on shares of Cytosorbents in a research note on Tuesday, January 9th. ValuEngine upgraded Cytosorbents from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. Finally, Maxim Group set a $12.00 price target on Cytosorbents and gave the company a “buy” rating in a research note on Monday, January 8th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $10.65.
A number of hedge funds have recently added to or reduced their stakes in CTSO. PNC Financial Services Group Inc. boosted its stake in Cytosorbents by 145.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 38,000 shares of the medical research company’s stock valued at $163,000 after purchasing an additional 22,500 shares during the last quarter. Fortaleza Asset Management Inc. boosted its stake in Cytosorbents by 81.6% during the 3rd quarter. Fortaleza Asset Management Inc. now owns 23,375 shares of the medical research company’s stock valued at $145,000 after purchasing an additional 10,500 shares during the last quarter. Wealthcare Advisory Partners LLC acquired a new position in Cytosorbents during the 3rd quarter valued at about $365,000. Skylands Capital LLC lifted its position in shares of Cytosorbents by 45.1% during the 4th quarter. Skylands Capital LLC now owns 725,608 shares of the medical research company’s stock worth $4,716,000 after buying an additional 225,558 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its position in shares of Cytosorbents by 182.3% during the 4th quarter. Wells Fargo & Company MN now owns 20,929 shares of the medical research company’s stock worth $136,000 after buying an additional 13,515 shares in the last quarter. Institutional investors and hedge funds own 9.53% of the company’s stock.
Shares of Cytosorbents (CTSO) opened at $7.68 on Thursday. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.36 and a quick ratio of 3.17. The company has a market capitalization of $220.20, a PE ratio of -23.98 and a beta of -0.19. Cytosorbents has a 12 month low of $3.30 and a 12 month high of $7.90.
Cytosorbents Company Profile
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.